

# Accepted Manuscript

Autoimmunity, Autoinflammation and Infection in Uveitis

John V. Forrester, Lucia Kuffova, Andrew D. Dick

PII: S0002-9394(18)30094-1

DOI: [10.1016/j.ajo.2018.02.019](https://doi.org/10.1016/j.ajo.2018.02.019)

Reference: AJOPHT 10430

To appear in: *American Journal of Ophthalmology*

Received Date: 24 August 2017

Revised Date: 22 February 2018

Accepted Date: 23 February 2018

Please cite this article as: Forrester JV, Kuffova L, Dick AD, Autoimmunity, Autoinflammation and Infection in Uveitis, *American Journal of Ophthalmology* (2018), doi: 10.1016/j.ajo.2018.02.019.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Abstract

### Purpose

To review the pathogenesis of uveitis in light of recent advances in our understanding of innate and adaptive immune responses and their regulation.

### Design

A perspective.

### Methods

The methods included a review of prevailing views on the pathogenesis of uveitis, and an analysis of developments in immunology which impact on its conceptual basis, particularly the concept of immunological tolerance and its loss in autoimmunity. Importantly, the role of infection in the pathogenesis of uveitis is evaluated.

### Results

The results comprise a re-appraisal of the pathogenesis of anterior versus posterior uveitis in the context of the blood-retinal barrier and its relation to autoimmune, auto-inflammatory and infectious uveitis. Autoimmunity is seen as a possible cause of certain forms of uveitis but definitive proof is lacking. Auto-inflammatory disease, involving activated innate immune mechanisms, is considered causative in a second set of uveitis conditions. A place for infection in uveitis generally is proposed within a unifying concept for the pathogenesis of uveitis.

### Conclusion

Infection may be implicated directly or indirectly in many forms of non-infectious or *undifferentiated* uveitis. In addition to the growing recognition that foreign antigen, including re-activatable infectious agents, might hide within ocular tissues, the possibility that a dysregulated microbiome might generate T cells which cause immune-mediated ocular inflammation has now been demonstrated experimentally. An uncontrolled, over-exuberant host immune response may cause continuing irreversible tissue damage even after the infection has been cleared.

**Autoimmunity, Autoinflammation and Infection in Uveitis**

John V Forrester <sup>\*#^</sup>, Lucia Kuffova <sup>\*,\*\*</sup>, Andrew D. Dick <sup>^^<<</sup>

\* Section of Immunology and Infection, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Science, Foresterhill, University of Aberdeen, Scotland, United Kingdom:

# Ocular Immunology Program, Centre for Ophthalmology and Visual Science, The University of Western Australia, Western Australia, 6009 Australia; and

^ Centre for Experimental Immunology, Lions Eye Institute, Nedlands, Western Australia, 6009 Australia

\*\* NHS Grampian, Aberdeen, Scotland, UK

^^ Translational Health Sciences (Ophthalmology), University of Bristol, Bristol, UK.

<< University College London, Institute of Ophthalmology and the National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital and UCL-Institute of Ophthalmology, London, UK.

Keywords: Uveitis, Autoimmunity, Autoinflammation, Infection

Suggested short title:

Autoimmunity, Autoinflammation and Infection in Uveitis

Corresponding author:

JV Forrester

Address:

University of Aberdeen  
Division of Applied Medicine  
Section of Immunology and Infection  
Institute of Medical Sciences  
Room 4.24  
Foresterhill  
Aberdeen  
AB25 2ZD  
Scotland, UK

Telephone 00 44 (1224) 437507

email [j.forrester@abdn.ac.uk](mailto:j.forrester@abdn.ac.uk)

Uveitis is a threat to vision, either directly or through ocular complications<sup>1</sup>. With a prevalence of 115-204 /100,000 population and incidence of 17-52 new cases / 100,000 per year in Northern California, uveitis is infrequent but because it affects all age groups carries a significant socio-economic burden<sup>2</sup>. Uveitis specialists categorize uveitis etiologically as either infectious or non-infectious<sup>3</sup>. Infections are proven causes of some cases of uveitis<sup>4-7</sup>. In others, activation of innate immune processes in response to infection may cause tissue damage through a mechanism of autoinflammation.

Non-infectious uveitis is not synonymous with autoimmune uveitis. The autoimmune hypothesis for non-infectious uveitis derives from experimental models of retinal inflammation that create blood-retinal barrier breakdown and stimulate adaptive immunity directed toward retinal antigenic targets. In non-retinal tissues, autoinflammatory or innate immune-mediated mechanisms may prevail. Because infectious agents usually drive autoinflammation, infection may underlie the pathogenesis of most uveitis, either through cytolytic tissue damage or through uncontrolled and dysregulated host immune responses that continue after infection subsides.

This perspective discusses evidence to support the concept that infection may be *more* and autoimmunity *less* involved in the pathogenesis of uveitis.

### ***Key role of blood retinal barrier in understanding the pathogenesis of uveitis***

***Uveitis*** as a universal term is not accurate regarding pathogenesis as other ocular components are often the inflammatory target. However, the uvea is consistently involved in intraocular inflammation, transporting more than 80% of the ocular blood volume, as well as managing the bulk flow of aqueous fluid<sup>8</sup>. The clinical classification of uveitis based on anterior, intermediate, posterior or panocular location<sup>3</sup> is insufficient when considering the pathogenesis of uveitis, which depends on whether the blood retinal barrier (BRB) is breached. Uveitis may be restricted to tissues external to the BRB, encompassing iritis, cyclitis, keratouveitis, sclerouveitis, and choroiditis, or uveitis may affect tissues normally protected by the BRB, including retinitis, retinal vasculitis, retinochoroiditis, and optic neuritis. In pathogenetic terms, ***posterior uveitis*** involves breakdown of the BRB while other forms of uveitis do not. Inflammation that involves compromise of the BRB is always associated with inflammation of the uveal tract but the reverse is not true. This distinction helps us to understand the etiology of uveitis.

### ***Is non-infectious uveitis autoimmune?***

Autoimmunity has been proposed as the pathogenesis for non-infectious uveitis<sup>9</sup>, paralleling the accepted pathogenesis of other organ specific autoimmune diseases<sup>10,11</sup>.

In principle, an autoimmune disease requires the identification of an autoantigen and an experimental model which resembles human disease<sup>12</sup>. Although both lens protein and uveal pigment have been proposed as potential autoantigens<sup>13</sup> extensive experimentation with uveal extracts has failed to produce

a reliable animal model that mirrors human uveitis. The retina contains several potent autoantigens that are expressed in the thymus<sup>14</sup> and in secondary lymphoid tissue<sup>15</sup> where immunological tolerance and prevention of autoimmune disease is maintained by a range of mechanisms, including clonal deletion and anergy. Genetic defects in the autoimmune regulator (AIRE) gene<sup>16</sup> are known to cause experimental and clinical autoimmune diseases, including a form of posterior uveitis<sup>17</sup>. Regulatory T cells (Treg) also maintain self-tolerance and control immune responses<sup>18, 19</sup>, including those in the retina<sup>20, 21</sup>. Autoimmunity to retinal autoantigens can be induced in several animal models including primates<sup>17</sup>. Experimental autoimmune uveitis (EAU) is considered a classical organ specific autoimmune disease that resembles posterior uveitis in man<sup>22</sup>. Despite the many insights that EAU reveals about into mechanisms of tissue damage in posterior uveitis, the model is difficult to translate to the wide range of human uveitic entities.

In EAU, there is extensive breakdown of the BRB<sup>23, 24</sup> with release of retinal autoantigens. Depending on context, these have the potential to activate the small number of self-antigen reactive T cells that have escaped thymic deletion and circulate in the periphery<sup>15</sup>. Accordingly there is a marked expansion of autoreactive T cells and autoantibodies to retinal antigens that can be detected in mice with EAU. Similar cellular or humoral immunological evidence is required to define autoimmune uveitis in humans. However, despite genetic conditions such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy/dysplasia (APECED)<sup>16</sup>, evidence for autoimmunity in undifferentiated non-infectious uveitis is sparse. Some clinical entities which are linked closely with restricted MHC genetic types such as Vogt-Koyanagi-Harada (VKH) disease<sup>25</sup>, sympathetic ophthalmia<sup>26, 27</sup> and birdshot retinochoroidopathy (BRC)<sup>28</sup> have the strongest claim to be *bona fide* autoimmune diseases. Of these, BRC may resemble diabetes mellitus as a potential CD8 T cell-mediated autoimmune disease in which presentation of cryptic peptide determinants of retinal S antigen<sup>29</sup> could theoretically be enhanced by presentation *via* HLA A29<sup>30</sup>.

Several studies have demonstrated that both humoral and cellular responses to a range of retinal antigens and their epitopes occur in patients with either infectious or undifferentiated uveitis<sup>31-33</sup>. Results have been inconsistent and self-reactivity to retinal antigens has been observed in healthy individuals<sup>32, 34-37</sup>. Similar confounding results have been observed in non-ocular diseases, and the number of definitive autoimmune diseases, in which autoreactive T cells or autoantibodies have been shown to be pathogenic, is limited. In addition, restoration of immunological tolerance in patients with diseases such as multiple sclerosis, rheumatoid arthritis and uveitis, although clearly effective in experimental models<sup>38</sup> that use experimental therapies such as mucosal tolerance induction, has not yet reached the clinic<sup>39</sup>.

Alternatively, a reduction in Tregs has been viewed as evidence that regulation of autoimmunity is impaired. However, the situation is complex. Circulating Tregs may be reduced in active disease but paradoxically may be increased in the tissues in both uveitis and rheumatoid arthritis<sup>40</sup>. The plasticity of Tregs and their possible interconversion with pathogenic T cells has also not helped to define immunoregulatory mechanisms<sup>41</sup>. In addition, because Tregs can control immune responses to both autoantigens and infectious agents<sup>18</sup> their involvement

does not help to differentiate autoimmune disease from post-infectious immune-mediated disease.

The above observations do not exclude autoimmune pathogenesis. For instance, autoimmune pathology may be part of a dual process arising later in disease evolution, such as *via* bystander damage in which release of autoantigen during an infectious condition leads to activation of autoreactive T cells. Indeed most recently, peptide therapy with the autoantigenic peptide, proinsulin in patients with early Type1 diabetes has been shown to delay progression of disease as measured by insulin requirement<sup>42</sup>. Perhaps a consistently identifiable target retinal autoantigen might allow a peptide therapy approach for secondary autoimmunity in human uveitis.

### ***Is non-infectious uveitis autoinflammatory?***

Autoinflammation and autoinflammatory disease are relatively recent concepts based on observations that patients with monogenic disorders affecting innate immune cells (predominantly myeloid cells such as macrophages and neutrophils) developed discrete syndromes, such as TNF-receptor associated periodic syndrome (TRAPS) and familial Mediterranean fever (FMF) (Table 1). Innate immune cells are central to classical autoimmune diseases due to their essential role in generating adaptive immunity (described by Janeway as “the immunologist’s dirty little secret”<sup>43</sup>). Animal models of autoimmunity, including EAU, require a bacterial adjuvant to stimulate innate immune cells, particularly dendritic cells<sup>44</sup>, which in turn activate specific T cells<sup>45</sup>. Pattern recognition receptors (PRR) recognize classes of micro-organisms by interaction with molecular patterns on pathogens (PAMPs) and then generate a range of T cells including Th1, Th17, Th9 ordinarily thought of as parts of the adaptive immune system<sup>46</sup>.

TRAPS was the first reported auto-inflammatory disease in humans. Its defining features are episodes of unprovoked ocular, periocular, and skin inflammation in the absence of high titres of autoantibodies or T cell responses. The condition results from spontaneous production of cytokines due to a missense mutation in p53, one of the proteins in the NF-kB complex<sup>47</sup>. Since then, several other auto-inflammatory conditions have been described (Table 1) and, as with discoveries relating to adaptive immunity, in which delineating the genetic defects in patients with T and B cell abnormalities revealed their physiological function<sup>48</sup>, mutations in genes controlling innate immune pathways have greatly assisted our understanding of how innate immunity is structured. Several classes of PAMPs have now been discovered, which activate specific signalling pathways through PRRs for bacteria, fungi, viruses, parasites and other foreign organisms and when these pathways are spontaneously activated, or homeostatic control dysregulated, they cause autoinflammatory diseases (Table 1).

Since many cases of uveitis are episodic, unprovoked and lack good evidence for specific autoantibodies or T cell responses to support an autoimmune pathogenesis, it has been suggested that at least some forms of uveitis may be autoinflammatory. Many monogenic autoinflammatory conditions involve activation of the inflammasome and are characterised by the secretion of IL-1 or one of its related molecules<sup>49</sup>. Importantly, skin /mucosal pathology in the form of vesicles or

ulceration is almost a common denominator. Uveitis features as part of the syndrome in several of these conditions<sup>50</sup> (Table 1). Moreover, the definition of autoinflammatory disease has been widening to an increasing list of complex genetic disorders, which includes Type 2 diabetes, macular degeneration and Behçet disease (Table 2).

A closer examination of uveitic conditions reveals some that might fit the description of autoinflammation in which there is evidence of activation of innate immune (myeloid) cells in the absence of a specific trigger. Some of these are polygenic systemic conditions in which uveitis may be part of the clinical presentation (Table 2). Candidate diseases include Behçet disease, JIA-associated anterior uveitis, pars planitis, intermediate uveitis, and tubulo-interstitial nephritis / uveitis (TINU) syndrome as well as others in which no auto-antigen has been identified, there are no representative animal models and clinical evidence for humoral or cell mediated autoimmunity is thin. In particular, the HLA B27-associated spondyloarthropathies, and presumably by association HLA B27-linked acute anterior uveitis, are considered by some to be autoinflammatory diseases [<sup>51</sup>] with a predisposition linked to protein misfolding and IL23 polymorphisms<sup>52</sup>. Both anterior and posterior uveitis occur in Behçet disease which resembles an autoinflammatory disease by its predominantly neutrophil-mediated pathology<sup>53</sup>.

Pathogenetically, it is unlikely that the full range of heterogeneous uveitis conditions can be attributed to autoinflammatory mechanisms. In this evolving field, unlabelled conditions with a positive response to blockade of IL-1 are preliminarily described as **undifferentiated** systemic autoinflammatory diseases (uSAIDs)<sup>54</sup>. Similarly, non-infectious uveitis has been re-branded as **undifferentiated** uveitis to signify the lack of a clear etiology<sup>55</sup>. In this context, uveitis associated with Behçet disease<sup>56</sup> and JIA has been reported to respond to anti-IL-1 therapy in small cohort studies. A larger study using the same criteria to investigate a range of non-Behçet posterior uveitis was inconclusive<sup>57</sup>. Despite the current uncertainty, increasing knowledge of the molecular signatures of disease seems likely to improve our understanding of the heterogeneity of uveitis.

### ***Is non-infectious uveitis caused by infection?***

Infectious agents have been implicated in the pathogenesis of autoimmune and autoinflammatory diseases generally. There is also a long-standing suspicion that the morbidity that results from many forms of ocular inflammatory disease derives from infection, either directly or by a dysregulated host response to infection. Non-infectious uveitis or undifferentiated uveitis is described as immune-mediated when no direct infectious cause can be identified but may in fact have been initiated by infection.

How infection might underpin the pathogenesis of uveitis relates to experimental models of autoimmune disease. Like most experimental models, EAU, a paradigmatic autoimmune disease<sup>17</sup>, requires mycobacterial extract and pertussis toxin to prime autoantigenic (IRBP)-specific Th1 and Th17 T cells, which target the retina and cause the disease. The mycobacterial extract commonly used to induce EAU is H37Ra which is an attenuated form of *Mycobacterium tuberculosis* (MTb) cultured from tissue samples of a patient with active tuberculosis<sup>58</sup>. MTb is rich in



PAMPS and activates the inflammasome and other pathways to release pro-inflammatory cytokines such as IL12, 23, 27 and IL-1. IL-1, the major cytokine driving autoinflammatory disease (see above section) is required for EAU induction by activating DC<sup>59</sup>. In contrast, tolerogenic DC which protect experimental mice against EAU, specifically fail to generate IL-1 when activated by MTb<sup>60</sup>.

MTb is believed to have infected up to a third of the world's population, the majority of whom remain latently infected, with a significant mortality rate<sup>61</sup>. MTb is a major cause of uveitis in humans, both in developed and developing countries<sup>62,63</sup> and presents in a large variety of clinical phenotypes, some of which are included in the category undifferentiated or non-infectious such as atypical serpinginous choroiditis<sup>64</sup>. How might MTb cause ocular inflammation? During the initial infection in the lung, myeloid cells (macrophages and DC) are specific targets of MTb that either kill or are killed by the MTb. In other cells, MTb evades killing and become latent within the cell. Latently infected myeloid cells traffic in and out of granulomas<sup>65</sup> and recirculate to reside in extrapulmonary sites such as the kidney, dermis, muscle, lymph nodes, meninges, and uveal tract where they can be reactivated at later times. If the pathogen thrives, a severe local infection with tissue damage (e.g. caseation) ensues. However, if the pathogen is contained, as in an immunocompetent individual, an over-exuberant host immune response to the reactivated MTb might then cause severe immune-mediated damage. In addition, at extrapulmonary sites of tissue damage, MTb antigen released from dead cells might act as a local adjuvant to innate immune cells which stochastically interact with autoreactive T cells in a bystander fashion and cause a secondary autoimmune reaction. Recent evidence for this secondary autoimmune reaction in patients with tuberculous uveitis has been reported<sup>66</sup>.

A link with infection or infectious material is difficult to identify in many cases either clinically and experimentally. For instance, spontaneous models of EAU occur in retinal antigen-specific T cell receptor transgenic mice without use of adjuvant<sup>67</sup>. However, exposure to microbial antigen still appears to be necessary since EAU fails to develop in these mice if they are bred in germ-free conditions<sup>68</sup>. In fact, even the standard model of IRBP / MTb-adjuvant-induced EAU cannot be induced in germ-free mice<sup>69</sup>. Remarkably, it appears that commensal antigen from the bowel activates antigen specific T cells which traffic to the retina and cause disease. These observations have considerable significance for the long known association between IBD, uveitis, and the spondyloarthropathies. Interestingly, not all commensal antigen is harmful; some commensals appear to protect from uveitis and so the context, and possible association with dysbiosis, might determine whether infection-associated immune-mediated uveitis occurs<sup>70</sup>. These clinical and experimental observations suggest that non-infectious, undifferentiated uveitis may be initiated by persistent, non-replicating micro-organisms or residual microbial antigen. The infectious etiology of chronic anterior uveitis caused by *Propionibacterium acnes* may not be immediately recognised. Similarly, recurrent chronic anterior uveitis due to herpes viruses often fails to yield active virus on investigation. Other forms of previously undifferentiated anterior and posterior uveitis are now recognised as being due to infection, such as hypertensive uveitis caused by CMV; Fuch's heterochromic uveitis due to rubella; and Chikungunya, West Nile virus, Dengue, and Rickettsia as causes of retinal vasculitis.



Much of the evidence for infection in these cases is not based on strict criteria of demonstrating replicating virus, but is simply based on viral DNA detected in ocular fluid or on serological evidence of a prior infection. As such, direct causative relationships between the infection and uveitis cannot be established but an adjuvant or, at least, an immune-mediated role whereby persistent antigen drives reactivation of resident memory T cells<sup>71, 72</sup>, can be envisaged. Recurrent uveitis might thus result either from reactivated replicating infectious agent or from a re-activated host immune-mediated response to an infectious agent. This has particular relevance, for instance, to uveitis associated with TB or toxoplasmosis where both anti-microbial therapy as well as immune-modulating agents may be required to minimise tissue damage but risk reactivating the latent micro-organism. In some cases viable replicating microbial agents have been demonstrated. The recent reports of late cultured virus from ocular and other tissue samples in patients who have recovered from Ebola, Zika and other viral infections indicate that viable virus persists in the tissues for long periods<sup>73-75</sup>.

This may be a common mechanism for the pathogenesis of disease, namely that if the host survives the initial infection, and the infectious agent is not completely cleared, then, to varying degrees, the organism persists undetected either as a viable infectious agent or as a residual antigenic pool which allows recurrent immune-mediated recrudescence of anti-microbe and/or anti-host (bystander effect) tissue damage. Perhaps an “either-or” approach to the pathogenesis of uveitis in terms of infection is too restrictive and a greater role for pathogens either as a direct effect (infectious uveitis) or as the cause of a dysregulated host response to pathogens once they have either been cleared or become latent (non-infectious, undifferentiated uveitis) offers a more unified pathogenetic framework.

### **Does the BRB regulate both infectious and non-infectious / undifferentiated uveitis?**

As argued in the first section of this Perspective, the pathogenesis of posterior uveitis, affecting the retina and optic nerve, is different from uveitis affecting sites outside the BRB. Retinal and CNS antigens are **protected** from damage by the BRB, which in the immunocompetent, healthy individual prevents both invasion by infectious agents and the passage of potentially damaging immune cells. It does this through two mechanisms: a physical barrier composed of the tight junctions of the retinal blood vessels and the retinal pigment epithelium (RPE), and an immunological barrier formed by cells of the neurovascular unit (retinal endothelium, perivascular macrophages, pericytes, microglia and the foot processes of glial cells forming the glia limitans)<sup>76, 77</sup> and by the RPE. The RPE in particular produces immunosuppressive mediators and, importantly, converts naïve T cells to Treg<sup>78-80</sup>.

Immune regulation at the BRB applies both to infectious and non-infectious uveitis. For example, infectious forms of uveitis which occur outside the BRB such as CMV- and HSV-induced anterior uveitis do not involve the retina unless the patient has lost immune regulatory control at the BRB. Thus, a CD4 count <50 cells/ml in untreated AIDS patients allows unchecked viral replication and CMV retinitis. When the CD4 count rises above 50, viral replication and infection in the retina can be

controlled but if the Treg / Teffector<sup>81, 82</sup> cell ratio is not normalised, cell immune-mediated uveitis ensues. Only if the BRB is physically broken or immunologically impaired as has been shown repeatedly in experimental animal models<sup>83</sup> can viral retinitis be induced.

The BRB presents both a physical and an immunological barrier to infectious agents and to circulating immune cells, and it serves in this capacity for both infectious uveitis in which damage is caused directly by the infecting agent, and non-infectious immune-mediated uveitis in which an uncontrolled, dysregulated immune response is the cause. An appropriate immune response that adequately clears any infection is clearly desirable. Regulating the host cellular immune response to the infectious agent or to an autoantigen, before either the infectious agent or the tissue damaging immune cells can cross the BRB, is also essential. Most infectious agents, particularly viruses and parasites, are held in check by the BRB but have ready access to other ocular tissues and cause uveitis either by replicating *in situ* in the acute phase or by inducing chronic / recurrent immune-mediated inflammation. In contrast, infectious agents that manage to cross the BRB either cause massive replicative end-stage damage or become latent (as in toxoplasmosis) mainly due to effective immunoregulatory mechanisms of the retinal parenchymal microenvironment.

## Conclusion

There is a growing awareness that while examples of autoimmune and autoinflammatory mechanisms have been well described and may explain the pathogenesis of uveitis, many cases of idiopathic or undifferentiated uveitis may ultimately be seen to be initiated by infection. Chronic inflammation and tissue damage may be the result of an exaggerated or dysregulated host response to the infection and the microbiome might be a significant source of infectious antigen and antigen-specific T cells. Thus, chronic or recurrent uveitic disease may be caused by local reactivations of persistent microbial agents or inadequately cleared antigen, including retroviral antigen, which intermittently disrupt the Treg / Teffector cell ratio. In addition, a dysregulated microbiome may predispose to, or even be the source of uveitogenic pathogens or adjuvants. Indeed, it is also likely that periodic episodes of uveitis in monogenic autoinflammatory diseases are driven by microbes that would normally be harmless in immunocompetent individuals.

## Disclosures

A Funding support: No funding support for this work.

B. Financial.

JVF: has received an honorarium for lecturing from Janssen, London, UK

LK: has undertaken consultancy work for Abbvie, London, UK

ADD: has undertaken consultancy work for Abbvie,( London, UK); Roche (London, UK); Genentech, London, UK; and has received honoraria from Janssen, London. UK and Abbvie, London, UK

## References

1. Dick AD, Tundia N, Sorg R, et al. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. *Ophthalmology* 2016;123:655-62.
2. Jabs DA. Epidemiology of uveitis. *Ophthalmic Epidemiol* 2008;15:283-4.
3. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol* 2005;140:509-16.
4. Hadjadj J, Dechartres A, Chapron T, et al. Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. *Autoimmun Rev* 2017;16:504-511.
5. Hoogewoud F, Frumholtz L, Loubet P, et al. Prognostic Factors in Syphilitic Uveitis. *Ophthalmology* 2017;124:1808-1816.
6. Mochizuki M, Sugita S, Kamoi K, Takase H. A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases. *Jpn J Ophthalmol* 2017;61:1-20.
7. Teoh SC, Dick AD. Diagnostic techniques for inflammatory eye disease: past, present and future: a review. *BMC Ophthalmol* 2013;13:41.
8. Forrester JV, Dick AD, McMenamin P, Pearlman E, Roberts F. *The Eye - Basic Science in Practice*, 4th Edition ed. London: Elsevier, 2015.
9. Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and autoinflammatory mechanisms in uveitis. *Semin Immunopathol* 2014;36:581-94.
10. Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. *Nat Rev Immunol* 2002;2:195-204.
11. Gomez-Tourino I, Arif S, Eichmann M, Peakman M. T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review. *J Autoimmun* 2016;66:7-16.
12. Margo CE, Harman LE. Autoimmune disease: Conceptual history and contributions of ocular immunology. *Surv Ophthalmol* 2016;61:680-8.
13. Woods AC. Disputed pathogeneses and entities in uveitis. *Am J Ophthalmol* 1958;45:251-68.
14. Takase H, Yu CR, Mahdi RM, et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. *Int Immunol* 2005;17:1131-40.

15. Voigt V, Wikstrom ME, Kezic JM, et al. Ocular antigen does not cause disease unless presented in the context of inflammation. *Sci Rep* 2017;7:14226.
16. Mathis D, Benoist C. *Aire*. *Annu Rev Immunol* 2009;27:287-312.
17. Caspi RR. A look at autoimmunity and inflammation in the eye. *J Clin Invest* 2010;120:3073-83.
18. Panduro M, Benoist C, Mathis D. Tissue Tregs. *Annu Rev Immunol* 2016;34:609-33.
19. Yu H, Paiva R, Flavell RA. Harnessing the power of regulatory T cells to control autoimmune diabetes: overview and perspective. *Immunology* 2017;153:161-170.
20. McPherson SW, Heuss ND, Pierson MJ, Gregerson DS. Retinal antigen-specific regulatory T cells protect against spontaneous and induced autoimmunity and require local dendritic cells. *J Neuroinflammation* 2014;11:205.
21. Silver PB, Horai R, Chen J, et al. Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. *J Immunol* 2015;194:3011-9.
22. Caspi RR. Understanding autoimmune uveitis through animal models. The Friedenwald Lecture. *Invest Ophthalmol Vis Sci* 2011;52:1872-9.
23. McMenamin PG, Forrester JV, Steptoe RJ, Dua HS. Ultrastructural pathology of experimental autoimmune uveitis. Quantitative evidence of activation and possible high endothelial venule-like changes in retinal vascular endothelium. *Lab Invest* 1992;67:42-55.
24. Greenwood J. The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. *Curr Eye Res* 1992;11 Suppl:25-32.
25. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. *Semin Ophthalmol* 2005;20:183-90.
26. Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. *Br J Ophthalmol* 2000;84:259-63.
27. Kilmartin DJ, Wilson D, Liversidge J, et al. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. *Br J Ophthalmol* 2001;85:281-6.
28. Kuiper J, Rothova A, de Boer J, Radstake T. The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers. *Prog Retin Eye Res* 2015;44:99-110.
29. Nussenblatt RB, Mittal KK, Ryan S, Green WR, Maumenee AE. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. *Am J Ophthalmol* 1982;94:147-58.
30. Prasad S, Starck SR, Shastri N. Presentation of Cryptic Peptides by MHC Class I Is Enhanced by Inflammatory Stimuli. *J Immunol* 2016;197:2981-2991.
31. Tripathi P, Saxena S, Yadav VS, Naik S, Singh VK. Human S-antigen: peptide determinant recognition in uveitis patients. *Exp Mol Pathol* 2004;76:122-8.
32. de Smet MD, Bitar G, Mainigi S, Nussenblatt RB. Human S-antigen determinant recognition in uveitis. *Invest Ophthalmol Vis Sci* 2001;42:3233-8.
33. Whittle RM, Wallace GR, Whiston RA, Dumonde DC, Stanford MR. Human antiretinal antibodies in toxoplasma retinochoroiditis. *Br J Ophthalmol* 1998;82:1017-21.

34. Ten Berge JC, Schreurs MW, Vermeer J, Meester-Smoor MA, Rothova A. Prevalence and clinical impact of antiretinal antibodies in uveitis. *Acta Ophthalmol* 2016;94:282-8.
35. Doekes G, Luyendijk L, Gerritsen MJ, Kijlstra A. Anti-retinal S-antigen antibodies in human sera: a comparison of reactivity in ELISA with human or bovine S-antigen. *Int Ophthalmol* 1992;16:147-52.
36. Forrester JV, Stott DI, Hercus KM. Naturally occurring antibodies to bovine and human retinal S antigen: a comparison between uveitis patients and healthy volunteers. *Br J Ophthalmol* 1989;73:155-9.
37. Vrabec TR, Reber RN, Magargal LE, Donoso LA. S-antigen. Identification of human T-cell lymphocyte proliferation sites. *Arch Ophthalmol* 1990;108:1470-3.
38. Huber A, Diedrichs-Mohring M, Wildner G. Spontaneously relapsing-remitting experimental autoimmune uveitis in rats allows successful therapeutic oral tolerance induction in ongoing disease. *Mol Immunol* 2015;63:215-26.
39. Nussenblatt RB. Bench to bedside: new approaches to the immunotherapy of uveitic disease. *Int Rev Immunol* 2002;21:273-89.
40. Morita T, Shima Y, Wing JB, Sakaguchi S, Ogata A, Kumanogoh A. The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis. *PLoS One* 2016;11:e0162306.
41. Kitz A, Dominguez-Villar M. Molecular mechanisms underlying Th1-like Treg generation and function. *Cell Mol Life Sci* 2017.
42. Alhadj Ali M, Liu YF, Arif S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. *Sci Transl Med* 2017;9.
43. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harb Symp Quant Biol* 1989;54 Pt 1:1-13.
44. Forrester JV, Xu H, Kuffova L, Dick AD, McMenamin PG. Dendritic cell physiology and function in the eye. *Immunol Rev* 2010;234:282-304.
45. Steinman RM. Decisions about dendritic cells: past, present, and future. *Annu Rev Immunol* 2012;30:1-22.
46. Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol* 2002;20:197-216.
47. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell* 1999;97:133-44.
48. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. *Nat Immunol* 2017;18:716-724.
49. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. *Mediators Inflamm* 2015;2015:194864.
50. Bascherini V, Granato C, Lopalco G, et al. The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. *Clin Rheumatol* 2015;34:1171-80.
51. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. *Nat Rev Rheumatol* 2015;11:338-48.
52. Sherlock JP, Taylor PC, Buckley CD, Cua DJ. Spondyloarthritis: interleukin 23 and disease modification. *Lancet* 2015;385:2017-8.

53. Gul A. Behcet's disease as an autoinflammatory disorder. *Curr Drug Targets Inflamm Allergy* 2005;4:81-3.
54. Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. *JCI Insight* 2016;1:e86336:1-15.
55. Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. *Am J Ophthalmol* 2013;156:228-36.
56. Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study. *Clin Rheumatol* 2017;36:191-197.
57. Schwartzman S, Schwartzman M. The Use of Biologic Therapies in Uveitis. *Clin Rev Allergy Immunol* 2015;49:307-16.
58. Steenken W, Oatway WH, Petroff SA. Biological Studies of the Tubercle Bacillus. III. Dissociation and Pathogenicity of the R and S variants of the human tubercle bacillus (H37). *J Exp Med* 1934;60:515-540.
59. Wan CK, He C, Sun L, Ekwuagu CE, Leonard WJ. Cutting Edge: IL-1 Receptor Signaling is Critical for the Development of Autoimmune Uveitis. *J Immunol* 2016;196:543-6.
60. Klaska IP, Muckersie E, Martin-Granados C, Christofi M, Forrester JV. Lipopolysaccharide-primed heterotolerant dendritic cells suppress experimental autoimmune uveoretinitis by multiple mechanisms. *Immunology* 2017;150:364-377.
61. WHO. Global tuberculosis Report, 2016.
62. Krassas N, Wells J, Bell C, Woodhead M, Jones N. Presumed tuberculosis-associated uveitis: rising incidence and widening criteria for diagnosis in a non-endemic area. *Eye (Lond)* 2017.
63. Abano JM, Galvante PR, Siopongco P, Dans K, Lopez J. Review of Epidemiology of Uveitis in Asia: Pattern of Uveitis in a Tertiary Hospital in the Philippines. *Ocul Immunol Inflamm* 2017;25:S75-S80.
64. Gupta V, Gupta A, Rao NA. Intraocular tuberculosis - an update. *Survey of Ophthalmology* 2007;52:561 - 587.
65. Appelmelk BJ, den Dunnen J, Driessen NN, et al. The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction. *Cell Microbiol* 2008;10:930-44.
66. Tagirasa R, Parmar S, Barik MR, Devadas S, Basu S. Autoreactive T Cells in Immunopathogenesis of TB-Associated Uveitis. *Invest Ophthalmol Vis Sci* 2017;58:5682-5691.
67. Chen J, Qian H, Horai R, Chan CC, Caspi RR. Mouse Models of Experimental Autoimmune Uveitis: Comparative Analysis of Adjuvant-Induced vs Spontaneous Models of Uveitis. *Curr Mol Med* 2015;15:550-7.
68. Horai R, Zarate-Blades CR, Dillenburg-Pilla P, et al. Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site. *Immunity* 2015;43:343-53.
69. Heissigerova J, Seidler Stangova P, Klimova A, et al. The Microbiota Determines Susceptibility to Experimental Autoimmune Uveoretinitis. *J Immunol Res* 2016;2016:5065703.



70. Nakamura YK, Metea C, Karstens L, et al. Gut Microbial Alterations Associated With Protection From Autoimmune Uveitis. *Invest Ophthalmol Vis Sci* 2016;57:3747-58.
71. Grossman Z, Paul WE. Dynamic tuning of lymphocytes: physiological basis, mechanisms, and function. *Annu Rev Immunol* 2015;33:677-713.
72. Hosokawa K, Muranski P, Feng X, et al. Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. *J Immunol* 2016;196:1568-78.
73. Hereth-Hebert E, Bah MO, Etard JF, et al. Ocular Complications in Survivors of the Ebola Outbreak in Guinea. *Am J Ophthalmol* 2017;175:114-121.
74. Henry CR, Al-Attar L, Cruz-Chacon AM, Davis JL. Chorioretinal Lesions Presumed Secondary to Zika Virus Infection in an Immunocompromised Adult. *JAMA Ophthalmol* 2017;135:386-389.
75. Merle H, Najioullah F, Chassery M, Cesaire R, Hage R. Zika-Related Bilateral Hypertensive Anterior Acute Uveitis. *JAMA Ophthalmol* 2017;135:284-285.
76. Trost A, Lange S, Schroedl F, et al. Brain and Retinal Pericytes: Origin, Function and Role. *Frontiers in cellular neuroscience* 2016;10:20-33.
77. Spadoni I, Fornasa G, Rescigno M. Organ-specific protection mediated by cooperation between vascular and epithelial barriers. *Nat Rev Immunol* 2017;17:761-773.
78. Imai A, Sugita S, Kawazoe Y, et al. Immunosuppressive properties of regulatory T cells generated by incubation of peripheral blood mononuclear cells with supernatants of human RPE cells. *Invest Ophthalmol Vis Sci* 2012;53:7299-309.
79. Kawazoe Y, Sugita S, Keino H, et al. Retinoic acid from retinal pigment epithelium induces T regulatory cells. *Exp Eye Res* 2012;94:32-40.
80. Vega JL, Saban D, Carrier Y, Masli S, Weiner HL. Retinal pigment epithelial cells induce foxp3(+) regulatory T cells via membrane-bound TGF-beta. *Ocul Immunol Inflamm* 2010;18:459-69.
81. Komatsu N, Takayanagi H. Regulatory T cells in Arthritis. *Prog Mol Biol Transl Sci* 2015;136:207-15.
82. Lee DJ, Taylor AW. Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. *J Leukoc Biol* 2015;97:1101-9.
83. Kezuka T, Atherton SS. Acute retinal necrosis. *Chem Immunol Allergy* 2007;92:244-53.



**Table 1****Title: Autoinflammatory Monogenic Disorders and Uveitis**

Condition	Gene affected	Mechanism	Uveitis	Ref
Familial Mediterranean Fever (FMF)	Pyrin (MEVF)	Increased inflammasome activity	yes	84
HIDS *	Mevalonate kinase	Increased inflammasome activity	Reviewed by Ter Haar	85
Muckle Wells syndrome	NLRP/cryopyrin	Inflammasomopathy	Yes	86
CAPS *	cryopyrin	Inflammasomopathy	yes	87
TRAPS *	TNF receptor 1	Protein misfolding	? (periocular inflammation)	88
NOMID *	NLRP / cryopyrin	Inflammasomopathy	Yes	89
Blau syndrome	NOD2 /CARD 15	NF-kB dysregulation	Yes	90
Pyoderma gangrenosum and acne <sup>91</sup>	PSTPIP1 / CD2BP1	PSTPIP1 → pyrin binding	No	
Deficiency in IL-1 receptor antagonist <sup>5</sup>	IL-1RN	Absence of IL-1Ra	No	
Majeed syndrome	Lip2 (Lipin-2)	? NLRP regulation defect	No	
HLH *	UNC13D, perforin, syntaxin	Macrophage activation	Yes	92
Gaucher's disease	GBA (acid glucosidase)	?	Yes	93
Aicardi-Goutier's syndrome	Trex gene	Failure of cDNA sensing by RIG-1	Chorioretinitis in Aicardi-like syndrome reported	94
CANDLE syndrome	PSMB8	Proteasome subunit defect	yes	95

Footnote: Uveitis, predominantly anterior, contributes the overall phenotype of several monogenic autoinflammatory disorders.

\* HIDS: hyperimmunoglobulinaemia D and periodic fever syndrome; CAPS: cryopyrin-associated periodic syndrome; TRAPS: tumor necrosis factor associated

periodic fever syndrome; NOMID: neonatal onset multisystem inflammatory disease; HLH: haemophagocytic lymphohistiocytosis

#### References:

84. Verbsky JW. Monogenic causes of inflammatory disease in rheumatology. *Curr Opin Rheumatol* 2012;24(5):506-14.
85. Ter Haar NM, Jeyaratnam J, Lachmann HJ, et al. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. *Arthritis Rheumatol* 2016;68(11):2795-2805.
86. Shakeel A, Gouvs P. Muckle-Wells syndrome: another casue of acute anterior uveitis. *Eye* 2007;21(6):849-850.
87. Kawai M, Yoshikawa T, Nishikomori R, Heike T, Takahashi K. Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome. *Clin Ophthalmol* 2013;7:1581-5.
88. Azizi G, Khadem Azarian S, Nazeri S, et al. Monogenic Auto-inflammatory Syndromes: A Review of the Literature. *Iran J Allergy Asthma Immunol* 2016;15(6):430-444.
89. Rosen-Wolff A, Quietzsch J, Schroder H, Lehmann R, Gahr M, Roesler J. Two German CINCA (NOMID) patients with different clinical severity and response to anti-inflammatory treatment. *Eur J Haematol* 2003;71(3):215-9.
90. Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. *Autoimmun Rev* 2014;13(12):1220-9.
91. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. *Cell* 1992;68(5):869-77.
92. Li X, Ma Y, Tang J, Chen T, Ma X. *Ocular Immunology and Inflammation* 2017;25:275-277.
93. Dweck A, Rozenman J, Ronen S, Zimran A, Elstein D. Uveitis in Gaucher disease. *Am J Ophthalmol* 2005;140(1):146-7.
94. Yu JT, Culican SM, Tychsen L. Aicardi-like chorioretinitis and maldevelopment of the corpus callosum in congenital lymphocytic choriomeningitis virus. *J AAPOS* 2006;10(1):58-60.
95. Al-Mayouf SM, AlSaleem A, AlMutairi N, et al. Monogenic interferonopathies: Phenotypic and genotypic findings of CANDLE syndrome and its overlap with C1q deficient SLE. *Int J Rheum Dis* 2017;21:208-213.

Table 2.

**Title: Multisystem disorders with possible autoinflammatory pathogenesis and their association with uveitis**

Condition	Gene(s)	Mechanism	Uveitis (ref)
Systemic onset JIA	?	? macrophage activation and IL1A gene	<sup>96, 97</sup>
Adult onset Still's disease	?	? overproduction of IL-1beta	
Schnitzler syndrome	? sporadic	Increased inflammasome activation	
Crohn's disease	NOD2/ATG16L1 IGRM	NF-kB dysregulation	<sup>98</sup>
CRMO*	?	? anti-IL6 responsive	
SAPHO *	?	? deficiency in FOXO1	<sup>99, 100</sup>
Gout	SLC2A(/GLUT9/ABCG2	crystallopathy	<sup>101</sup>
Pseudogout	?	crystallopathy	
Type 2 diabetes	?	glucose → inflammasome activation	
Atypical haemolytic uremic syndrome	CFH, CD46, CFI, CFB	abnormal regulation of C3b	
Age-related macular degeneration	CFH	failed inactivation of C3b, inflammasome activation	
Behcet's disease	?	increased inflammasome activation	<sup>102, 103</sup>
Atherosclerosis	?	? dysregulated macrophage activation	
Asbestosis	?	particles → inflammasome activation	
HLA B27 spondyloarthropathies	MHC Class I (B27)	misfolded protein → inflammasome activation	<sup>104</sup>

Footnote: An increasing number of polygenic, multisystem diseases may have an autoinflammatory pathogenesis; uveitis, both posterior and anterior, are prominent features of some of these conditions

\* CRMO: chronic recurrent multifocal osteomyelitis; SAPHO: synovitis-acne-pustulosis-hyperostosis-osteitis

## References:

1. Dick AD, Tundia N, Sorg R, et al. Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. *Ophthalmology* 2016;123(3):655-62.
2. Jabs DA. Epidemiology of uveitis. *Ophthalmic Epidemiol* 2008;15(5):283-4.
3. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. *Am J Ophthalmol* 2005;140(3):509-16.
4. Hadjadj J, Dechartres A, Chapron T, et al. Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. *Autoimmun Rev* 2017;16(5):504-511.
5. Hoogewoud F, Frumholtz L, Loubet P, et al. Prognostic Factors in Syphilitic Uveitis. *Ophthalmology* 2017;124:1808-1816.
6. Mochizuki M, Sugita S, Kamoi K, Takase H. A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases. *Jpn J Ophthalmol* 2017;61(1):1-20.
7. Teoh SC, Dick AD. Diagnostic techniques for inflammatory eye disease: past, present and future: a review. *BMC Ophthalmol* 2013;13(1):41. doi: 10.1186/1471-2415-13-41.
8. Forrester JV, Dick AD, McMenamin P, Pearlman E, Roberts F. *The Eye - Basic Science in Practice, 4th Edition ed. London: Elsevier, 2015.*
9. Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and autoinflammatory mechanisms in uveitis. *Semin Immunopathol* 2014;36(5):581-94.
10. Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. *Nat Rev Immunol* 2002;2(3):195-204.
11. Gomez-Tourino I, Arif S, Eichmann M, Peakman M. T cells in type 1 diabetes: Instructors, regulators and effectors: A comprehensive review. *J Autoimmun* 2016;66:7-16.
12. Margo CE, Harman LE. Autoimmune disease: Conceptual history and contributions of ocular immunology. *Surv Ophthalmol* 2016;61(5):680-8.
13. Woods AC. Disputed pathogeneses and entities in uveitis. *Am J Ophthalmol* 1958;45 (4 Pt2):251-68.
14. Takase H, Yu CR, Mahdi RM, et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. *Int Immunol* 2005;17(8):1131-40.
15. Voigt V, Wikstrom ME, Kezic JM, et al. Ocular antigen does not cause disease unless presented in the context of inflammation. *Sci Rep* 2017;7(1):14226. doi: 10.1038/s41598-017-14618-z.
16. Mathis D, Benoist C. Aire. *Annu Rev Immunol* 2009;27:287-312.
17. Caspi RR. A look at autoimmunity and inflammation in the eye. *J Clin Invest* 2010;120(9):3073-83.
18. Panduro M, Benoist C, Mathis D. Tissue Tregs. *Annu Rev Immunol* 2016;34:609-33.
19. Yu H, Paiva R, Flavell RA. Harnessing the power of regulatory T cells to control autoimmune diabetes: overview and perspective. *Immunology* 2017;153:161-170.

20. McPherson SW, Heuss ND, Pierson MJ, Gregerson DS. Retinal antigen-specific regulatory T cells protect against spontaneous and induced autoimmunity and require local dendritic cells. *J Neuroinflammation* 2014;11:205 -219.
21. Silver PB, Horai R, Chen J, et al. Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. *J Immunol* 2015;194(7):3011-9.
22. Caspi RR. Understanding autoimmune uveitis through animal models. The Friedenwald Lecture. *Invest Ophthalmol Vis Sci* 2011;52:1872-9.
23. McMenamin PG, Forrester JV, Steptoe RJ, Dua HS. Ultrastructural pathology of experimental autoimmune uveitis. Quantitative evidence of activation and possible high endothelial venule-like changes in retinal vascular endothelium. *Lab Invest* 1992;67(1):42-55.
24. Greenwood J. The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. *Curr Eye Res* 1992;11 Suppl:25-32.
25. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. *Semin Ophthalmol* 2005;20(3):183-90.
26. Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. *Br J Ophthalmol* 2000;84(3):259-63.
27. Kilmartin DJ, Wilson D, Liversidge J, et al. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. *Br J Ophthalmol* 2001;85(3):281-6.
28. Kuiper J, Rothova A, de Boer J, Radstake T. The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers. *Prog Retin Eye Res* 2015;44:99-110.
29. Nussenblatt RB, Mittal KK, Ryan S, Green WR, Maumenee AE. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. *Am J Ophthalmol* 1982;94(2):147-58.
30. Prasad S, Starck SR, Shastri N. Presentation of Cryptic Peptides by MHC Class I Is Enhanced by Inflammatory Stimuli. *J Immunol* 2016;197(8):2981-2991.
31. Tripathi P, Saxena S, Yadav VS, Naik S, Singh VK. Human S-antigen: peptide determinant recognition in uveitis patients. *Exp Mol Pathol* 2004;76(2):122-8.
32. de Smet MD, Bitar G, Mainigi S, Nussenblatt RB. Human S-antigen determinant recognition in uveitis. *Invest Ophthalmol Vis Sci* 2001;42(13):3233-8.
33. Whittle RM, Wallace GR, Whiston RA, Dumonde DC, Stanford MR. Human antiretinal antibodies in toxoplasma retinochoroiditis. *Br J Ophthalmol* 1998;82(9):1017-21.
34. Ten Berge JC, Schreurs MW, Vermeer J, Meester-Smoor MA, Rothova A. Prevalence and clinical impact of antiretinal antibodies in uveitis. *Acta Ophthalmol* 2016;94(3):282-8.
35. Doekes G, Luyendijk L, Gerritsen MJ, Kijlstra A. Anti-retinal S-antigen antibodies in human sera: a comparison of reactivity in ELISA with human or bovine S-antigen. *Int Ophthalmol* 1992;16(3):147-52.
36. Forrester JV, Stott DI, Hercus KM. Naturally occurring antibodies to bovine and human retinal S antigen: a comparison between uveitis patients and healthy volunteers. *Br J Ophthalmol* 1989;73(2):155-9.
37. Vrabec TR, Reber RN, Magargal LE, Donoso LA. S-antigen. Identification of human T-cell lymphocyte proliferation sites. *Arch Ophthalmol* 1990;108(10):1470-3.

38. Huber A, Diedrichs-Mohring M, Wildner G. Spontaneously relapsing-remitting experimental autoimmune uveitis in rats allows successful therapeutic oral tolerance induction in ongoing disease. *Mol Immunol* 2015;63(2):215-26.
39. Nussenblatt RB. Bench to bedside: new approaches to the immunotherapy of uveitic disease. *Int Rev Immunol* 2002;21(2-3):273-89.
40. Morita T, Shima Y, Wing JB, Sakaguchi S, Ogata A, Kumanogoh A. The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis. *PLoS One* 2016;11(9):e0162306.
41. Kitz A, Dominguez-Villar M. Molecular mechanisms underlying Th1-like Treg generation and function. *Cell Mol Life Sci* 2017; 74 (22):4059- 4075
42. Alhadj Ali M, Liu YF, Arif S, et al. Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. *Sci Transl Med* 2017;9(402). doi: 10.1126/scitranslmed.aaf7779
43. Janeway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harb Symp Quant Biol* 1989;54 Pt 1:1-13.
44. Forrester JV, Xu H, Kuffova L, Dick AD, McMenamin PG. Dendritic cell physiology and function in the eye. *Immunol Rev* 2010;234(1):282-304.
45. Steinman RM. Decisions about dendritic cells: past, present, and future. *Annu Rev Immunol* 2012;30:1-22.
46. Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol* 2002;20:197-216.
47. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell* 1999;97(1):133-44.
48. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. *Nat Immunol* 2017;18(7):716-724.
49. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. *Mediators Inflamm* 2015;2015:194864. doi: 10.1155/2015/194864.
50. Bascherini V, Granato C, Lopalco G, et al. The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. *Clin Rheumatol* 2015;34(7):1171-80.
51. Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. *Nat Rev Rheumatol* 2015;11(6):338-48.
52. Sherlock JP, Taylor PC, Buckley CD, Cua DJ. Spondyloarthropathy: interleukin 23 and disease modification. *Lancet* 2015;385(9982):2017-8.
53. Gul A. Behcet's disease as an autoinflammatory disorder. *Curr Drug Targets Inflamm Allergy* 2005;37(4):81-3.
54. Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. *JCI Insight* 2016;1(6):e86336:1-15.
55. Jabs DA, Busingye J. Approach to the diagnosis of the uveitides. *Am J Ophthalmol* 2013;156(2):228-36.
56. Fabiani C, Vitale A, Emmi G, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis: a multicenter retrospective observational study. *Clin Rheumatol* 2017;36(1):191-197.



57. Schwartzman S, Schwartzman M. The Use of Biologic Therapies in Uveitis. *Clin Rev Allergy Immunol* 2015;49(3):307-16.
58. Steenken W, Oatway WH, Petroff SA. Biological Studies of the Tubercle Bacillus. III. Dissociation and Pathogenicity of the R and S variats of the human tubercle bacillus (H37). *J Exp Med* 1934;60:515-540.
59. Wan CK, He C, Sun L, Egwuagu CE, Leonard WJ. Cutting Edge: IL-1 Receptor Signaling is Critical for the Development of Autoimmune Uveitis. *J Immunol* 2016;196(2):543-6.
60. Klaska IP, Muckersie E, Martin-Granados C, Christofi M, Forrester JV. Lipopolysaccharide-primed heterotolerant dendritic cells suppress experimental autoimmune uveoretinitis by multiple mechanisms. *Immunology* 2017;150(3):364-377.
61. WHO. Global tuberculosis Report, 2016.
62. Krassas N, Wells J, Bell C, Woodhead M, Jones N. Presumed tuberculosis-associated uveitis: rising incidence and widening criteria for diagnosis in a non-endemic area. *Eye (Lond)* 2017. doi: 10.1038/eye.2017.152
63. Abano JM, Galvante PR, Siopongco P, Dans K, Lopez J. Review of Epidemiology of Uveitis in Asia: Pattern of Uveitis in a Tertiary Hospital in the Philippines. *Ocul Immunol Inflamm* 2017;25:S75-S80.
64. Gupta V, Gupta A, Rao NA. Intraocular tuberculosis - an update. *Survey of Ophthalmology* 2007;52:561 - 587.
65. Appelmek BJ, den Dunnen J, Driessen NN, et al. The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction. *Cell Microbiol* 2008;10(4):930-44.
66. Tagirasa R, Parmar S, Barik MR, Devadas S, Basu S. Autoreactive T Cells in Immunopathogenesis of TB-Associated Uveitis. *Invest Ophthalmol Vis Sci* 2017;58(13):5682-5691.
67. Chen J, Qian H, Horai R, Chan CC, Caspi RR. Mouse Models of Experimental Autoimmune Uveitis: Comparative Analysis of Adjuvant-Induced vs Spontaneous Models of Uveitis. *Curr Mol Med* 2015(6);15:550-7.
68. Horai R, Zarate-Blades CR, Dillenburg-Pilla P, et al. Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site. *Immunity* 2015;43(2):343-53.
69. Heissigerova J, Seidler Stangova P, Klimova A, et al. The Microbiota Determines Susceptibility to Experimental Autoimmune Uveoretinitis. *J Immunol Res* 2016;2016:5065703. doi:10.1155/2016/5065703
70. Nakamura YK, Metea C, Karstens L, et al. Gut Microbial Alterations Associated With Protection From Autoimmune Uveitis. *Invest Ophthalmol Vis Sci* 2016;57(8):3747-58.
71. Grossman Z, Paul WE. Dynamic tuning of lymphocytes: physiological basis, mechanisms, and function. *Annu Rev Immunol* 2015;33:677-713.
72. Hosokawa K, Muranski P, Feng X, et al. Memory Stem T Cells in Autoimmune Disease: High Frequency of Circulating CD8+ Memory Stem Cells in Acquired Aplastic Anemia. *J Immunol* 2016;196(4):1568-78.
73. Hereth-Hebert E, Bah MO, Etard JF, et al. Ocular Complications in Survivors of the Ebola Outbreak in Guinea. *Am J Ophthalmol* 2017;175(3):114-121.



74. Henry CR, Al-Attar L, Cruz-Chacon AM, Davis JL. Chorioretinal Lesions Presumed Secondary to Zika Virus Infection in an Immunocompromised Adult. *JAMA Ophthalmol* 2017;135(4):386-389.
75. Merle H, Najioullah F, Chassery M, Cesaire R, Hage R. Zika-Related Bilateral Hypertensive Anterior Acute Uveitis. *JAMA Ophthalmol* 2017;135(3):284-285.
76. Trost A, Lange S, Schroedl F, et al. Brain and Retinal Pericytes: Origin, Function and Role. *Frontiers in cellular neuroscience* 2016;10:20-33.
77. Spadoni I, Fornasa G, Rescigno M. Organ-specific protection mediated by cooperation between vascular and epithelial barriers. *Nat Rev Immunol* 2017;17(12):761-773.
78. Imai A, Sugita S, Kawazoe Y, et al. Immunosuppressive properties of regulatory T cells generated by incubation of peripheral blood mononuclear cells with supernatants of human RPE cells. *Invest Ophthalmol Vis Sci* 2012;53(11):7299-309.
79. Kawazoe Y, Sugita S, Keino H, et al. Retinoic acid from retinal pigment epithelium induces T regulatory cells. *Exp Eye Res* 2012(1);94:32-40.
80. Vega JL, Saban D, Carrier Y, Masli S, Weiner HL. Retinal pigment epithelial cells induce foxp3(+) regulatory T cells via membrane-bound TGF-beta. *Ocul Immunol Inflamm* 2010;18(6):459-69.
81. Komatsu N, Takayanagi H. Regulatory T cells in Arthritis. *Prog Mol Biol Transl Sci* 2015;136:207-15.
82. Lee DJ, Taylor AW. Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. *J Leukoc Biol* 2015;97(6):1101-9.
83. Kezuka T, Atherton SS. Acute retinal necrosis. *Chem Immunol Allergy* 2007;92:244-53.
84. Verbsky JW. Monogenic causes of inflammatory disease in rheumatology. *Curr Opin Rheumatol* 2012;24(5):506-14.
85. Ter Haar NM, Jeyaratnam J, Lachmann HJ, et al. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. *Arthritis Rheumatol* 2016;68(11):2795-2805.
86. Shakeel A, Gouvs P. Muckle-Wells syndrome: another casue of acute anterior uveitis. *Eye* 2007;21(6):849-850.
87. Kawai M, Yoshikawa T, Nishikomori R, Heike T, Takahashi K. Obvious optic disc swelling in a patient with cryopyrin-associated periodic syndrome. *Clin Ophthalmol* 2013;7:1581-5.
88. Azizi G, Khadem Azarian S, Nazeri S, et al. Monogenic Auto-inflammatory Syndromes: A Review of the Literature. *Iran J Allergy Asthma Immunol* 2016;15(6):430-444.
89. Rosen-Wolff A, Quietzsch J, Schroder H, Lehmann R, Gahr M, Roesler J. Two German CINCA (NOMID) patients with different clinical severity and response to anti-inflammatory treatment. *Eur J Haematol* 2003;71(3):215-9.
90. Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. *Autoimmun Rev* 2014;13(12):1220-9.
91. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. *Cell* 1992;68(5):869-77.

92. Li X, Ma Y, Tang J, Chen T, Ma X. *Ocular Immunology and Inflammation* 2017;25:275-277.
93. Dweck A, Rozenman J, Ronen S, Zimran A, Elstein D. Uveitis in Gaucher disease. *Am J Ophthalmol* 2005;140(1):146-7.
94. Yu JT, Culican SM, Tychsen L. Aicardi-like chorioretinitis and maldevelopment of the corpus callosum in congenital lymphocytic choriomeningitis virus. *J AAPOS* 2006;10(1):58-60.
95. Al-Mayouf SM, AlSaleem A, AlMutairi N, et al. Monogenic interferonopathies: Phenotypic and genotypic findings of CANDLE syndrome and its overlap with C1q deficient SLE. *Int J Rheum Dis* 2017;21:208-213.
96. Heiligenhaus A, Minden K, Foll D, Pleyer U. Uveitis in juvenile idiopathic arthritis. *Dtsch Arztebl Int* 2015;112(6):92-100, i.
97. Artornsombudh P, Pistilli M, Foster CS, et al. Factors predictive of remission of new-onset anterior uveitis. *Ophthalmology* 2014;121(3):778-84.
98. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn's disease. *Autoimmun Rev* 2014;13(4-5):467-71.
99. Yabe H, Takano Y, Nomura E, et al. Two cases of SAPHO syndrome accompanied by classic features of Behcet's disease and review of the literature. *Clin Rheumatol* 2008;27(1):133-5.
100. Caravatti M, Wiesli P, Uebelhart D, Germann D, Welzl-Hinterkorn E, Schulthess G. Coincidence of Behcet's disease and SAPHO syndrome. *Clin Rheumatol* 2002;21(4):324-7.
101. Sharon Y, Schlesinger N. Beyond Joints: a Review of Ocular Abnormalities in Gout and Hyperuricemia. *Curr Rheumatol Rep* 2016;18(6):37.
102. Leccese P, Yazici Y, Olivieri I. Behcet's syndrome in nonendemic regions. *Curr Opin Rheumatol* 2017;29(1):12-16.
103. Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet's disease: epidemiology, clinical manifestations, and diagnosis. *Expert Rev Clin Immunol* 2017;13(1):57-65.
104. Rosenbaum JT. New developments in uveitis associated with HLA B27. *Curr Opin Rheumatol* 2017;29(4):298-303.